Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis

被引:158
作者
Boonen, A
van den Heuvel, R
van Tubergen, A
Goossens, M
Severens, JL
van der Heijde, D
van der Linden, S
机构
[1] Univ Hosp Maastricht, Dept Internal Med, Div Rheumatol, NL-6202 AZ Maastricht, Netherlands
[2] Univ Maastricht, Fac Med, Maastricht, Netherlands
[3] Univ Maastricht, Dept Med Clin & Expt Psychol, Maastricht, Netherlands
[4] Univ Maastricht, Dept Hlth Org Policy & Econ, Maastricht, Netherlands
关键词
D O I
10.1136/ard.2003.019711
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To compare the cost of illness of three musculoskeletal conditions in relation to general wellbeing. Methods: Patients with fibromyalgia, chronic low back pain (CLBP), and ankylosing spondylitis who were referred to a specialist and participated in three randomised trials completed a cost diary for the duration of the study, comprising direct medical and non-medical resource utilisation and inability to perform paid and unpaid work. Patients rated perceived wellbeing (0-100) at baseline. Univariate differences in costs between the groups were estimated by bootstrapping. Regression analyses assessed which variables, in addition to the condition, contributed to costs and wellbeing. Results: 70 patients with fibromyalgia, 110 with chronic low back pain, and 111 with ankylosing spondylitis provided data for the cost analyses. Average annual disease related total societal costs per patient were E7813 for fibromyalgia, E8533 for CLBP, and E3205 for ankylosing spondylitis. Total costs were higher for fibromyalgia and CLBP than for ankylosing spondylitis, mainly because of cost of formal and informal care, aids and adaptations, and work days lost. Wellbeing was lower in fibromyalgia (mean, 48) and low back pain (mean, 42) than in ankylosing spondylitis (mean, 67). No variables other than diagnostic group contributed to differences in costs or wellbeing. Conclusions: In patients under the care of a specialist, there were marked differences in costs and wellbeing between those with fibromyalgia or CLBP and those with ankylosing spondylitis. In particular, direct non-medical costs and productivity costs were higher in fibromyalgia and CLBP.
引用
收藏
页码:396 / 402
页数:7
相关论文
共 24 条
[1]  
[Anonymous], 2000, DIAGNOSTIC STAT MANU
[2]  
BAKKER C, 1994, J RHEUMATOL, V21, P269
[3]   METHODOLOGIC CHALLENGES IN THE DEVELOPMENT OF UTILITY MEASURES OF HEALTH-RELATED QUALITY-OF-LIFE IN RHEUMATOID-ARTHRITIS [J].
BENNETT, K ;
TORRANCE, G ;
TUGWELL, P .
CONTROLLED CLINICAL TRIALS, 1991, 12 (04) :S118-S128
[4]   Direct costs of ankylosing spondylitis and its determinants:: an analysis among three European countries [J].
Boonen, A ;
van der Heijde, D ;
Landewé, R ;
Guillemin, F ;
Rutten-van Mölken, M ;
Dougados, M ;
Mielants, H ;
de Vlam, K ;
van der Tempel, H ;
Boesen, S ;
Spoorenberg, A ;
Schouten, H ;
van der Linden, S .
ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (08) :732-740
[5]   Work status and productivity costs due to ankylosing spondylitis:: comparison of three European countries [J].
Boonen, A ;
van der Heijde, D ;
Landewé, R ;
Spoorenberg, A ;
Schouten, H ;
Rutten-van Mölken, M ;
Guillemin, F ;
Dougados, M ;
Mielants, H ;
de Vlam, K ;
van der Tempel, H ;
van der Linden, S .
ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (05) :429-437
[6]  
Goossens MEJB, 1996, J RHEUMATOL, V23, P1246
[7]   The cost diary:: a method to measure direct and indirect costs in cost-effectiveness research [J].
Goossens, MEJB ;
Rutten-van Mölken, MPH ;
Vlaeyen, JWS ;
van der Linden, SMJP .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2000, 53 (07) :688-695
[8]  
Goossens MEJB, 1998, HEALTH ECON, V7, P39, DOI 10.1002/(SICI)1099-1050(199802)7:1<39::AID-HEC323>3.0.CO
[9]  
2-S
[10]  
HIDDING A, 1994, J RHEUMATOL, V21, P818